Gain Therapeutics Files 8-K Report

Ticker: GANX · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1819411

Gain Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyGain Therapeutics, Inc. (GANX)
Form Type8-K
Filed DateJun 30, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 8-k, other-events

TL;DR

Gain Therapeutics filed an 8-K on 6/30/25 for 'Other Events' - details TBD.

AI Summary

On June 30, 2025, Gain Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no specific details provided in the provided text regarding the nature of these events, any associated financial figures, or other named parties.

Why It Matters

This filing signals a material event has occurred for Gain Therapeutics, Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in this excerpt.

Risk Assessment

Risk Level: medium — The filing of an 8-K for 'Other Events' suggests a material development, but the lack of specific details introduces uncertainty and potential risk for investors.

Key Players & Entities

  • Gain Therapeutics, Inc. (company) — Registrant
  • June 30, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 001-40237 (identifier) — Commission File Number
  • 85-1726410 (identifier) — I.R.S. Employer Identification No.
  • 4800 Montgomery Lane , Suite 220 Bethesda , Maryland 20814 (address) — Principal executive offices
  • ( 301 ) 500-1556 (phone_number) — Registrant's telephone number

FAQ

What specific event(s) are being reported under 'Other Events' by Gain Therapeutics, Inc.?

The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported by Gain Therapeutics, Inc.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on June 30, 2025.

What is the principal executive office address for Gain Therapeutics, Inc.?

The principal executive office address for Gain Therapeutics, Inc. is 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.

What is the Commission File Number for Gain Therapeutics, Inc.?

The Commission File Number for Gain Therapeutics, Inc. is 001-40237.

What is the fiscal year end for Gain Therapeutics, Inc.?

The fiscal year end for Gain Therapeutics, Inc. is December 31 (1231).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Gain Therapeutics, Inc. (GANX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.